Prostate cancer (PCa) risk in patients with multiple sclerosis (MS) remains to be elucidated. The present study conducted a meta-analysis to assess the relationship between MS and PCa. PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched to identify studies on the PCa risk in patients with MS up to September 2022. A random effects meta-analyses model was performed to estimate the relative risk (RR) and the 95% confidence intervals (CI). All eight studies involving 210,943 patients with MS were identified and included in the meta-analysis. The present study revealed that there was no significant association between MS and the risk of PCa (RR=0.78, 95% CI: 0.56-1.08, P<0.0001). Subgroup analyses verified this conclusion when stratified by regions. However, after adjusting for potential confounders, the findings suggested conflicting results. The current evidence shows that compared with the population control, patients with MS have no relationship with PCa risk and further large samples and long-term trials are needed to verify these results.
Clear cell renal cell carcinoma (ccRCC) is the most common pathology type of renal cancer that has an abysmal prognosis. Although a crucial role for 7-methylguanosine modification in cancer cell development has been reported, its role in ccRCC remains uncertain. This study was conducted to determine the efficacy of predictive biomarkers based on m7G-related genes in ccRCC. Firstly, we extracted clinical data and gene expression profiles of ccRCC patients from publicly accessible databases. It identified that 22 of the m7G-related 34 genes were related to overall survival, and 5 of the 22 genes were significantly expressed differently in tumor tissues. Based on Lasso regression analysis, five optimal genes (CYFIP2, EIF4A1, NUDT1, NUDT10, and NUDT4) were chosen to build a new predictive risk model in the TCGA cohort. Validation was carried out with the E-MTAB-1980 cohort. Then, a prognostic nomogram was erected, including the m7G-related gene risk score, age, histological grade, and stage status. Further studies and analysis showed that immune cell infiltration might be associated with the m7G-related risk genes. In addition, the relationship between gene expression and drug response was evaluated by the Pearson correlation test. Therefore, the risk signature with five selected m7G-related genes may be a promising prognostic biomarker and contribute to standardized prognostic assessment for ccRCC.
Backgrounds:Clear cell renal cell carcinoma (ccRCC) is a form of renal tumor with poor prognosis and insensitive to radiotherapy and chemotherapy. HSD3B7 is highly expressed in a variety of malignant tumors and is associated with poor prognosis. However, the role of HSD3B7 in clear cell renal cell carcinoma (ccRCC) is unclear. The purpose of this study is to determine the role of HSD3B7 in ccRCC by integrated bioinformatics analysis. Methods: The whole transcriptome data were downloaded from the Cancer Genome Atlas (TCGA) database. The expression and methylation data of HSD3B7 mRNA were obtained from TIMER, UALCAN and MethSurv databases. Linkedomics database is used to study the functional pathway of the genes co-expressed with HSD3B7. The TIMER and TISIDB databases were used to analyze the correlation between HSD3B7 and tumor infiltrating immune cells and immune modulators. The expression of HSD3B7 in different tumor cell lines and its relationship with drug response were analyzed by RNAactDrug and CCLE database. Results:The expression of HSD3B7 was significantly up-regulated in most cancer types. The mRNA and protein expression levels of HSD3B7 were significantly higher in normal tissues compared with ccRCC tissues. Kaplan-Meier survival curve showed that high HSD3B7 expression level predicted poor OS and PFS. The degree of DNA methylation of HSD3B7 in ccRCC was significantly lower than that in normal tissues. The pathway function enrichment analysis of HSD3B7 co-expressed genes suggested that HSD3B7 co-expressed genes were mainly involved in immune-related pathways. At the same time, the expression of HSD3B7 was also strongly correlated with immune infiltration level, immune regulators and chemokines. More importantly, the results of drug sensitivity suggested that the expression of HSD3B7 was closely related to the mechanism of many common renal cell carcinoma related drugs. Therefore, HSD3B7 can be a potential prognostic and prognostic biomarker and therapeutic target of ccRCC. Conclusions:The results suggested that HSD3B7 may be a potential prognostic biomarker and a new therapeutic target for ccRCC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.